Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 817

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 817
---
 |     |                    |     2 |   |     |      |     (1 | ) |
| Accrued expenses                                                             |     |                    |   172 |   |     |      |   (831 | ) |
| Net cash used for operating activities                                       |     |                    |  (399 | ) |     |      | (2,159 | ) |
| Financing activities                                                         |     |                    |       |   |     |      |        |   |
| Proceeds from related party loans                                            |     |                    | 1,230 |   |     |      |  2,164 |   |
| Payments of deferred offering costs                                          |     |                    |  (836 | ) |     |      |      — |   |
| Net cash provided by financing activities                                    |     |                    |   394 |   |     |      |  2,164 |   |
| Net change in cash and cash equivalents                                      |     |                    |    (5 | ) |     |      |      5 |   |
| Cash and cash equivalents at beginning of period                             |     |                    |    12 |   |     |      |     12 |   |
| Cash and cash equivalents at end of period                                   |     | $                  |     7 |   |     | $    |     17 |   |

See accompanying notes to unaudited condensed financial statements F-89

SEMNUR PHARMACEUTICALS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

Note 1. Nature of Operations and Basis of Presentation

Organization and Principal Activities

Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) was formed in 2013 and became a wholly owned subsidiary of Scilex Holding
Company (“Scilex”) in 2019. The Company is a late clinical stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. The Company is
currently developing one product candidate, SP-102 (10 mg, dexamethasone sodium phosphate viscous gel), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat
lumbosacral radicular pain, or sciatica, for which the Company has completed a pivotal Phase 3 study (“SP-102” or “SEMDEXA”). Since inception, the Company has devoted all of its efforts